Real-Life Efficacy of Palbociclib and Ribociclib in Advanced Breast Cancer
Current Oncology · 2025
DOI: 10.3390/curroncol32030161 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Tugay Avci und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45030, Turkey. Hauptthemen laut MEDLINE: Breast Neoplasms, Purines, Aminopyridines, Piperazines. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Clinical trials in metastatic hormone receptor-positive (HR+) human epidermal growth factor receptor-2 (HER2)-negative patients have shown that cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors both increase response rates and provide survival benefits. The efficacy of these therapies needs to be supported by real-life data. In this study, we aimed to evaluate treatment response, survival and affecting factors in patients with HR+/HER2− metastatic breast cancer (MBC) who were followed up with CDK 4/6 inhibitors in our center. Materials and methods: A retrospective analysis of 120 patients with HR+/HER2− MBC treated with ribociclib or palbociclib in combination with letrozole or fulvestrant was performed.
Results
Median progression-free survival (mPFS) was 24 months in the general population, 27 months in the ribociclib arm and 20 months in the palbociclib arm, with no significant difference in progression-free survival (PFS) in both arms (p = 0.25). The mPFS was longer in the ribociclib + letrozole arm compared to palbociclib + letrozole (27 vs. 20 months, respectively). PFS was also longer in patients receiving ribociclib + fulvestrant compared to palbociclib + fulvestrant but not statistically significant (33 vs. 21 months, respectively). Median overall survival (mOS) was not reached, but 3-year overall survival (OS) was statistically significantly longer in the ribociclib arm (87% vs. 55.5%, respectively, p = 0.03).
Conclusion
Palbociclib and ribociclib are first-line treatment options for metastatic HR+/HER2− disease and have similar efficacy. In our study, while the mPFS was not statistically significant in both arms, the 3-year OS rate was higher in the ribociclib arm and statistically significant. Our findings were confirmed in randomized studies comparing both agents head-to-head.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45030, Turkey.
ORCID-Profile: Tugay Avci, Mustafa Sahbazlar, Ferhat Ekinci, Atike Pinar Erdogan
Zitieren
APA
Avci, T., Sahbazlar, M., Ekinci, F., & Erdogan, A. P. (2025). Real-Life Efficacy of Palbociclib and Ribociclib in Advanced Breast Cancer. Current Oncology. https://doi.org/10.3390/curroncol32030161
Vancouver
Avci T, Sahbazlar M, Ekinci F, Erdogan AP. Real-Life Efficacy of Palbociclib and Ribociclib in Advanced Breast Cancer. Current Oncology. 2025. doi:10.3390/curroncol32030161
BibTeX
@article{Avci2025,
author = {Avci, Tugay and Sahbazlar, Mustafa and Ekinci, Ferhat and Erdogan, Atike Pinar},
title = {Real-Life Efficacy of Palbociclib and Ribociclib in Advanced Breast Cancer},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32030161}
}
EUVIMED